share_log

WEED Australia Ltd Is Proud to Announce the Appointment of Ms. Amanda Brunskill-Scott and Mrs. Nicole Breen as Members of Our Board of Directors

WEED Australia Ltd Is Proud to Announce the Appointment of Ms. Amanda Brunskill-Scott and Mrs. Nicole Breen as Members of Our Board of Directors

WEED Australia Ltd 自豪地宣佈任命阿曼達·布倫斯基爾-斯科特女士和妮可·布雷恩夫人爲我們的董事會成員
Accesswire ·  2023/05/18 05:00

Ms. Brunskill-Scott will also take over the role of Managing Director and Corporate Secretary, while Mrs. Breen will take over the additional role and responsibilities of treasurer.

布倫斯基爾-斯科特女士還將接任董事董事總經理和公司祕書,布林女士將接任財務主管的額外角色和職責。

TUCSON, AZ / ACCESSWIRE / May 17, 2023 / WEED Inc. (OTCQB:BUDZ), ("WEED" or the "Company") a global cannabis & hemp bioresearch company based in the USA, focused on the development and application of cannabis-derived compounds for the treatment of human and animal diseases.

亞利桑那州圖森/ACCESSWIRE/2023年5月17日/雜草公司(OTCQB:巴茲),(“大麻”或“公司”)是一家總部設在美國的全球大麻和大麻生物研究公司,專注於開發和應用大麻衍生化合物,用於治療人類和動物疾病。

Wholly owned subsidiary HEMP Biosciences Inc. is pleased to announce that it received its hemp cultivation license from the state of Arizona. The license allows for cultivation, process and manufacture of hemp for the production of low THC & CBD products.

全資子公司大麻生物科學公司高興地宣佈,它從亞利桑那州獲得了大麻種植許可證。許可證允許種植、加工和製造大麻,用於生產低THC和CBD產品。

In addition, Ms. Brunskill-Scott has been appointed as our in-house counsel for both WEED Australia Limited and the Cannabis Institute of Australia. While Mr. Patrick Brodnik, will continue to promote the Corporate Business Development for WEED Inc. USA and continue working on strategic partnerships and cannabis acquisitions for WEED Australia Limited.

此外,布倫斯基爾-斯科特女士已被任命為我們為WIDD澳大利亞有限公司和澳大利亞大麻研究所提供的內部法律顧問。帕特裡克·布羅德尼克先生將繼續為美國威德公司促進企業業務發展,並繼續為威德澳大利亞有限公司從事戰略合作夥伴關係和大麻收購工作。

We would like to take this opportunity to express our heartfelt gratitude to Mr. John J. Foley, who recently retired from our Australian management & Board of Directors. Glenn E. Martin CEO comments, "John has been a faithful servant to our company since the beginning, and we wish him a well-deserved retirement at the young age of 85 years old. We look forward to his continued advice and counsel in the future."

我們願藉此機會向最近從澳大利亞管理層和董事會退休的約翰·J·福利先生表示衷心的感謝。首席執行官格倫·E·馬丁表示:“約翰從一開始就是我們公司的忠實僕人,我們祝願他在85歲高齡時退休。我們期待他在未來繼續提供建議和忠告。”

Ms. Brunskill-Scott is an advocate for the indigenous peoples of Australia and grew up in the Northern Territory, as her family is both indigenous Australians and from Papa New Guinea. Her appointment to our Board of Directors reflects our commitment to diversity and inclusion, and we are excited to have her leadership and vision driving our company forward. Darwin and the Far Northern Territories such as Cape York which are top of our list for cannabis cultivation.

布倫斯基爾-斯科特女士是澳大利亞土著人民的倡導者,在北領地長大,因為她的家人既是澳大利亞土著居民,也來自新幾內亞爸爸。她被任命為董事會成員反映了我們對多元化和包容性的承諾,我們很高興她的領導和遠見推動我們的公司向前發展。達爾文和遠北地區,如約克角,在我們的大麻種植名單上名列前茅。

Ms. Brunskill-Scott announces, "I'm excited and privileged for the opportunity before me to lead the team WEED Australia has established over the past 7 years. Surviving Covid hardships has strengthened our resolve to find natural plant remedies to complex medical conditions. WEED Australia and the Cannabis Institute looks to lead the charge in cannabis research and product development making it affordable to all compared to the current market situation."

布倫斯基爾-斯科特女士宣佈:“我為有機會領導澳大利亞大麻公司在過去7年中建立的團隊感到興奮和榮幸。Covid的艱難生存增強了我們尋找針對複雜醫療條件的天然植物藥物的決心。大麻澳大利亞公司和大麻研究所希望在大麻研究和產品開發方面發揮帶頭作用,使其與當前的市場形勢相比,使所有人都能負擔得起。”

Mrs. Breen states, "The cannabis industry in Australia is on the global forefront. WEED was incorporated in March 2017 as an ASIC regulated entity. Post Covid WEED looks to ready an IPO for the ASX once economic condition warrants. I am excited to work with Amanda and bring WEED Australia to its full potential in the cannabis and hemp space.

Breen夫人說:“澳大利亞的大麻產業走在了全球前列。威德於2017年3月被納入ASIC監管實體。一旦經濟條件允許,Post Covid Wide有望為澳大利亞證券交易所的首次公開募股做好準備。我很高興能與阿曼達合作,讓威德澳大利亞在大麻和大麻領域充分發揮其潛力。

WEEDs key to success is our rare Landrace cannabis genetics grown and kept F-1 grade over 40-50 years, while scientific research and development will ensure year over year returns for our investors as we build a premier cannabis company in Australia."

雜草成功的關鍵是我們罕見的Landrace大麻基因在40-50年內種植並保持F-1級,而科學研究和開發將確保我們的投資者年復一年地獲得回報,因為我們在澳大利亞建立了一家頂級的大麻公司。“

WEED Australia Ltd is dedicated to developing innovative products and services for the Australian people utilizing the amazing cannabaceae plant.

威德澳大利亞有限公司致力於利用令人驚嘆的大麻植物為澳大利亞人民開發創新的產品和服務。

Our nonprofit arm, the Cannabis Institute of Australia, is focused on cannabis & hemp research including clinical trials for pharma and non-pharma product and services.

我們的非營利性機構澳大利亞大麻研究所專注於大麻和大麻研究,包括製藥和非製藥產品和服務的臨床試驗。

With the appointment of Ms. Brunskill-Scott and Mrs. Breen, we are confident that WEED Australia Limited as a majority owned subsidiary of WEED Inc (USA) will continue to grow and thrive as a global cannabis holding company. WEED Australia Ltd. formed in March 2017 was the first cannabis pubco, ASIC regulated, in Australia with an American parent.

隨著布倫斯基爾-斯科特女士和布林夫人的任命,我們相信,作為威德公司(美國)的多數股權子公司,威德澳大利亞有限公司將繼續作為一家全球大麻控股公司發展壯大。威德澳大利亞有限公司成立於2017年3月,是澳大利亞第一家有美國母公司的大麻酒吧,受到ASIC的監管。

WEED, Inc.'s Subsidiaries past comments:

威德股份有限公司的S子公司過去發表評論:

WEED Israel (Cannabis) Ltd. "After over 3 years of putting human clinical trials and product development on hold due to COVID, WEED Israel is poised and anxious to build out our global brands in both pharmaceutical and non-pharmaceutical categories, starting with women's health and veterans' ailments (PTSD) to healthy green alternative medicines" stated Elliot Kwestel, Managing Director of WEED Israel (Cannabis) Ltd. based outside Jerusalem.

Kwestel further commented, "WEED Israel looks to enrich and expand our clinical trials with both THC and Cannabinoid studies to promote healthy living for generations to come."

威德以色列(大麻)有限公司總部設在耶路撒冷外的VIDE以色列(大麻)有限公司的董事經理埃利奧特·奎斯特爾說:“在由於柯維德病而擱置人類臨床試驗和產品開發三年多之後,VIDE以色列公司已經做好準備,急於在製藥和非製藥類別建立我們的全球品牌,從婦女健康和退伍軍人疾病(PTSD)到健康的綠色替代藥物。

Kwestel進一步評論說:“威德以色列希望通過THC和大麻素研究豐富和擴大我們的臨床試驗,以促進子孫後代的健康生活。”

WEED Australia Ltd. and The Cannabis Institute of Australia (C.I.A.), our Australian non-profit arm, based in Queensland on the Gold Coast.

Corporate Director Patrick Brodnik stated, "With the new rules out governing cannabis & hemp in Australia and the announcement in February 2021 to allow over-the-counter CBD medicines in pharmacies, now after Covid, timing is perfect to begin our clinical trials in Israel and Australia to bring new curative products to market as we close out COVID mandates this year.

Managing Director Brunskill-Scott commented "Next year 2024, the future of USA & Australia decriminalizing cannabis and hemp globally will prove to be a giant leap forward for worldwide cannabis legalization."

威德澳大利亞有限公司澳大利亞大麻研究所(CIA),我們的澳大利亞非營利性機構,總部設在黃金海岸的昆士蘭。

董事公司帕特裡克·布羅德尼克說:“隨著澳大利亞禁止大麻和大麻的新規定,以及2021年2月宣佈允許藥店使用CBD非處方藥,現在是Covid之後,開始我們在以色列和澳大利亞的臨床試驗的完美時機,隨著我們今年結束CoVID的授權,將把新的治療產品推向市場。

董事管理公司布倫斯基爾-斯科特評論說:“到2024年,美國和澳大利亞將大麻和大麻在全球範圍內合法化的未來將被證明是全球大麻合法化的巨大飛躍。”

WEED Hong Kong Ltd. Director Nicole Breen agrees, "The pandemic has affected all of us on a worldwide basis. Healing our planet with natural therapies, treatments and eventual "cures" utilizing natures' own Cannabaceae plant with its many properties, both with high tetrahydrocannabinol (THC) and cannabidiol (CBD) compounds, I believe will change the force of medicine forever in the years to come. We look forward to an exciting year end and a Prosperous 2022."

雜草香港有限公司董事妮可·布林同意這一觀點:“這場流行病已經在全球範圍內影響了我們所有人。用自然療法治癒我們的星球,最終‘治癒’利用大自然自己的大麻科植物的許多特性,包括高四氫大麻酚(THC)和大麻二酚(CBD)化合物,我相信在未來的幾年裡將永遠改變醫學的力量。我們期待著一個令人興奮的年底和繁榮的2022年。”

Caution Regarding Cannabis Operations in the United States:

關於在美國的大麻業務的警告:

Any Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis.

任何投資者都應該注意到,美國有管理大麻行業的重大法律限制和法規。雖然大麻在某些州是合法的,但根據美國受控物質法案,大麻仍然是第一類藥物,根據美國聯盟法律,種植、分銷或擁有大麻等行為是非法的。

That all Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation. That Investors should carefully read the risk factors and disclosures contained in our offering circular before making any decision to invest in our company.

所有涉及在美國與大麻有關的商業活動所產生的收益或旨在促進與大麻有關的商業活動的收益的金融交易,均可構成根據適用的美國聯盟洗錢法進行起訴的依據。投資者在作出投資本公司的任何決定前,應仔細閱讀我們的發售通告中包含的風險因素和披露。

Forward Looking Information:

前瞻性資訊:

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "potential", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to any future revenue and profits.

本新聞稿包含適用證券法所指的“前瞻性資訊”。本新聞稿中包含的前瞻性資訊可以通過使用“可能”、“潛在”、“將”、“可能”、“將”、“可能”、“預期”、“預期”、“相信”、“打算”、“計劃”、“預測”、“專案”、“估計”、“展望”和其他類似的表述來識別,包括關於任何未來收入和利潤的陳述。

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

前瞻性資訊並不是對未來業績的保證,而是基於管理層的經驗和對趨勢、當前狀況和預期發展的看法以及其他與情況相關的因素對管理層的一系列估計和假設,包括對當前和未來市場狀況、當前和未來監管環境的假設;以及許可證、批准和許可的可獲得性。

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct.

儘管公司認為這些前瞻性資訊所基於的預期和假設是合理的,但不應過度依賴前瞻性資訊,因為公司不能保證它們將被證明是正確的。

Actual results and developments may differ materially from those contemplated by these statements.

實際結果和發展可能與這些陳述中預期的大不相同。

Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this press release are made as of the date of this release.

前瞻性資訊會受到各種風險和不確定性的影響,這些風險和不確定性可能會導致實際事件或結果與前瞻性資訊中預測的大不相同。本新聞稿中的陳述是在本新聞稿發佈之日作出的。

That the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws for the relevant country.

除相關國家/地區適用的證券法要求外,公司不承擔任何因新資訊、未來事件或結果或其他原因而更新任何前瞻性資訊的意圖或義務。

Legal Notice:

法律公告:

That the information is provided for convenience only, it is not investment advice and may not be relied upon in considering an investment in WEED, Inc.

這些資訊僅為方便起見而提供,不是投資建議,在考慮投資威德公司時可能不會依賴。

That No representation or warranty, express or implied, is made as to the accuracy or completeness of any information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related materials, and the investors independent research.

對於本文所包含的任何資訊的準確性或完整性,不作任何明示或暗示的陳述或擔保,任何投資決定應完全基於發售通告和相關材料中包含的資訊以及投資者的獨立研究。

We advise that No representations or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will or are likely to achieve favorable results, will make any profit at all or will be able to avoid incurring a loss on their investment.

我們建議,對於對WIDD,Inc.的任何投資的未來表現,或投資者將或可能獲得有利的結果、將獲得任何利潤或將能夠避免其投資虧損,不作任何明示或暗示的陳述或擔保。

In addition, all prospective investors are encouraged to consult with their financial, tax, accounting, or other advisors to determine whether an investment in WEED, Inc. is suitable for them.

此外,鼓勵所有潛在投資者諮詢他們的財務、稅務、會計或其他顧問,以確定對WIDE,Inc.的投資是否適合他們。

Media Contact:

媒體聯繫人:

Glenn E. Martin, CEO
1-520-818-8582
Glenn@WEEDincUSA.com

格倫·E·馬丁,首席執行官
1-520-818-8582
郵箱:glenn@WEEDincUSA.com

SOURCE: WEED Inc.

資料來源:威德公司


View source version on accesswire.com:
在Accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論